The Scientific Intelligence Layer for Connected Clinical Trial Decisions

Bringing a new therapeutic to market is one of the most complex endeavors in modern science, and despite decades of technological progress, the underlying economics have not improved. Clinical development costs $100 billion annually, yet 90% of drugs fail. Phase II go/no-go calls are too often made on incomplete evidence, and the consequences compound downstream: a single Phase III protocol amendment costs, on average, $535,000, and 80% of trials face chronic delays.